CYP.AX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 bal. 2024 @ 09:10):

Stats
Dzisiejszy wolumen	121 419
Średni wolumen	173 845
Kapitalizacja rynkowa	37.72M
EPS	$0 ( 2024-02-26 )
Następna data zysków	( $0 ) 2024-07-23
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.33
ATR14	$0.00100 (0.48%)

Cynata Therapeutics Ltd Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cynata Therapeutics Ltd Finanse

Annual	2023
Przychody:	$1.65M
Zysk brutto:	$1.37M (83.08 %)
EPS:	$-0.0984

FY	2023
Przychody:	$1.65M
Zysk brutto:	$1.37M (83.08 %)
EPS:	$-0.0984

FY	2022
Przychody:	$7.77M
Zysk brutto:	$7.49M (96.40 %)
EPS:	$-0.0380

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.0590

Financial Reports:

No articles found.

Cynata Therapeutics Ltd

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.